ArticleBritish journal of clinical pharmacology2026
Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: Evidence from the prospective CENTRA cohort.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: Evidence from the prospective CENTRA cohort.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe cardiovascular risk of tofacitinib has been highly concerned. In this study, we investigated the trajectory of lipid profiles in patients with rheumatoid arthritis (RA) after receiving tofacitinib.
methodsPatients were recruited from the prospective CENTRA cohort of RA patients. The data of RA disease activity, triglyceride (TG), total cholesterol (TCHO), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and ratios of TCHO/HDL and LDL/HDL were collected at baseline, week 4, 12, 24 and 52. Lipid and lipoprotein concentrations were compared between the tofacitinib exposure group and the non-exposure group by propensity score matching (PSM).
resultsTotally 374 patients were enrolled, with 137 received tofacitinib and 237 not. After 4 weeks of tofacitinib treatment, the levels of TG, TCHO, HDL and LDL were increased. TCHO and LDL concentrations returned to baseline levels by weeks 24 and 52, respectively, while TG and HDL levels remained elevated throughout 52 weeks. After 1:1 PSM, 133 patients in tofacitinib exposure group and 133 in non-exposure group were identified. Compared to the non-exposure group, the tofacitinib-exposure group showed significantly increased TCHO levels at week 4 and continuously higher TCHO levels till week 24; HDL and LDL levels were also elevated from week 12 to week 24.
conclusionsFour-week exposure to tofacitinib induced elevation of TG, TCHO, HDL and LDL in serum. LDL and TCHO returned to baseline levels at week 24 and week 52, respectively; nevertheless, TG and HDL displayed continued elevated levels. Tofacitinib exposure was generally associated with a more remarkable elevation of lipid profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.